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Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease that
can affect major organs possibly leading to life-threatening complications and appears
with heterogeneous clinical picture. SLE could present with broad spectrum of clinical
and laboratory features that can resemble those of other diseases, such as hemopoietic
malignancies, infections, or immune-mediated disorders. Its complexity and protean
features overlap with many other diseases, hindering the differential diagnosis. Rarely,
true overlap with other diseases may occur. Herein, we report a case series of two
patients affected by infectious diseases, namely visceral leishmaniasis and Whipple’s
disease (WD), intertwined with clinical or serological features of SLE. In both cases,
several confounding factors have led to a delay in the diagnosis. Moreover, we first
describe the persistent elevation of autoantibodies and a monoclonal gammopathy in a
patient with WD. Awareness of unusual presentations of infections or other rare
disorders, which may be encountered in clinical practice when taking care of SLE
patients, is essential for timely diagnosis and treatment of potentially lethal diseases.
Keywords: systemic lupus erythematous, visceral leishmaniasis, Whipple’s
disease, monoclonal gammopathy of undetermined significance, fever, splenomegaly,
aplasia
Introduction
Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease
that can affect major organs possibly leading to life-threatening complications and
presents with a heterogeneous clinical picture. Despite many studies have
investigated its causes, the etiology remains poorly understood [1].
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SLE more frequently affects women than men (ratio 9:1), primarily during
reproductive periods. The most widely used classification criteria for SLE were
developed by the American College of Rheumatology (ACR) [2, 3]. A patient has
to fulfill at least 4 of these 11 criteria to be classified as having SLE.
SLE could present with broad spectrum of clinical and laboratory features
that can resemble those of other diseases, such as hemopoietic malignancies,
infections, or immune-mediated disorders. Moreover, the clinical picture can be
complicated by manifestations due to drug side effects, infections, and other
comorbid disorders. On the other hand, various diseases can mimic SLE flares,
making the differential diagnosis difficult. The misdiagnosis of these conditions
may cause delays in appropriate treatment and lead to the inadequate use of
immunosuppressive drugs with potentially dangerous effects [4].
SLE is a disease known as one of the “great imitators”: its complexity and
protean features overlap with many other diseases, hindering the differential
diagnosis. Rarely, true overlap with other diseases may occur [5, 6].
Herein, we report two patients affected by rare infectious disorders inter-
twined with SLE.
Case report 1
A 52-year-old woman was referred to our department presenting protein-
uria (1.53 g/24 h) since 3 months and fever, intense fatigue, and migrant arthritis
at the referral time. Laboratory workup evidenced anemia, thrombocytopenia,
elevated erythrocyte sedimentation rate (ESR) and C-reactive protein levels,
positivity of antinuclear antibody (ANA) 1:160 with homogeneous pattern, and
anti-ds-DNA antibody to 45.3 IU/ml (Farr assay). According to the ACR criteria,
she was diagnosed with SLE and initially treated with intravenous methylpred-
nisolone pulses and then prednisone (25 mg) daily associated with hydroxy-
chloroquine (400 mg) daily. Since partial clinical and laboratory response was
achieved after 2 months, the patient underwent intravenous cyclophosphamide
(CYC) pulses (750 mg monthly). Ten days after the first pulse, she was admitted
to our wards presenting fever (39 °C peak), severe thrombocytopenia (8,000/μl),
severe neutropenia (300/μl), anemia [hemoglobin (Hb) 6.6 g/dl], and
hepatosplenomegaly. An empirical therapy with different combinations of
broad-spectrum antibiotics (levofloxacin, ceftriaxone, meropenem, gentamicin,
teicoplanin, clarithromycin, and linezolid) was started together with antifungal
therapy (fluconazole). Iatrogenic bone marrow aplasia was suspected; thus,
immunosuppressive treatment was discontinued and the patient underwent blood
and platelet transfusions and administrations of lenograstim (recombinant
human G-CSF). No bone marrow biopsy was performed, as the consultant
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hematologist was confident of an iatrogenic cause of aplasia. Due to persistence
of fever, intravenous amphotericin B substituted fluconazole after 15 days. After
20 days of aplasia, her condition was improved, with decrease of fever and
gradual recovery of bone marrow function. The patient was discharged afebrile
with greatly improved conditions. Immunosuppressive therapy for SLE was
reintroduced with mycophenolate mofetil 2,000 mg/day and oral prednisone.
Two months later, the patient started to present fever and fatigue. The
persistence of hepatosplenomegaly was observed and serum protein electropho-
resis revealed a suspected monoclonal gammopathy, not documented before.
Urinary immunofixation revealed a monoclonal component of kappa free-light
chains and serum immunofixation a monoclonal component IgG-K. Bone marrow
aspirate and biopsy showed the presence of normal erythroid and myeloid series;
mature lymphocytes <10%, plasma cells and blast proportion <5%, but
unexpectedly there was a striking presence of small elements within the cytoplasm
of histiocytes and macrophages consistent with leishmania infestation (Figure 1).
High titers of serum anti-leishmania antibodies were demonstrated (≥30 antibody
units).
Immunosuppressive therapy was discontinued and high dose of
liposomal amphotericin B, i.e., 3 mg/kg (total dose = 1,400 mg), was adminis-
tered. In the following 3 weeks, fever and weakness gradually disappeared and
inflammatory markers normalized. The monoclonal component gradually de-
creased until it disappeared after approximately 1 year as well as autoantibody
positivity.
Figure 1. Leishmania phagocytosed by the macrophages in bone marrow blood smear
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Case report 2
A 30-year-old woman presented with 1-year history of 7 kg weight loss, fever,
and night sweats. In 2006, she was diagnosed with epithelioid granulomatous
necrotizing lymphadenopathy. In 2011, a gastroenteritis by Salmonella species, and
hypochromic microcytic anemia resistant to iron therapy had been diagnosed and
treated. Physical examination revealed lymph nodes of about 1 cm in the right
cervical area. Laboratory values were as follows: Hb 8.2 g/dl; elevated ESR to
54 mm/h, ANA positive in a titer 1:640, anti-ds-DNA 85.1 UI/ml, and RNP
33 UI/ml. Serum immunofixation revealed a monoclonal IgG-lambda component.
Computed tomography imaging showed hepatomegaly and multiple enlarged and
confluent lymph nodes of the hepatic hilum, para-aortic, mesenteric, and iliac region.
Bone marrow aspirate and biopsy, cancer markers, colonoscopy, screening for celiac
disease, quantiferon, fecal cultures, and calprotectin levels were normal. Suspecting a
lymphoproliferative disorder, a laparoscopic abdominal lymph node biopsy was
performed. Histology showed aggregates of foamy periodic acid–Schiff positive and
diastase-resistant histiocytes containing abundant cytoplasmatic granular material,
compatible with Whipple’s disease (WD). Analysis by polymerase chain reaction
(PCR) of 16S rRNA of biopsy tissue confirmed the diagnosis [7]. Revision of the
cervical lymph node biopsy performed in 2006 was also suggestive of WD. The
esophagogastroduodenoscopy and bowel biopsies of the upper gastrointestinal tract
were normal.
Therapy with intravenous ceftriaxone and then with oral sulfamethoxazole/
trimethoprim was established. One month after the antibiotic therapy, the general
conditions, inflammatory markers, and complete blood counts started to improve.
Furthermore, after 6 months, a thyroid biopsy showed the presence of a papillary
carcinoma. Total thyroidectomy was performed. To date, the partial normalization
of antibody values has been documented after 18 months of antibiotic therapy: Hb
12.2 g/dl, ESR 30 mm/h, ANA positive in a titer 1:640, anti-ds-DNA to 8.0 UI/ml
(normal reference <7 IU/ml), and anti-RNP to 17 UI/ml. Monoclonal component
is still detectable.
Discussion
Several studies have investigated the role of infectious agents in the
pathogenesis of SLE, hypothesizing that the disease may be the consequence of
an uncontrolled immune response against pathogens in susceptible individuals
[8, 9]. Molecular mimicry, superantigens, epitope spreading, bystander activation,
and activation of lymphocytes by lymphotropic viruses are commonly suggested
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as main mechanisms involved in the triggering of the autoimmune response [10].
The association of viral infections for the production of autoantibodies and lupus-
like disorders has been widely reported in literature [11]. Most of the evidences are
available for Epstein-Barr virus [12], but some authors suggested that parvovirus
B19, retrovirus such as Human T-lymphotropic virus type-1 and cytomegalovirus
might be involved in the pathogenesis [13–16].
SLE is an autoimmune disease characterized by B-cell activation, which
plays a crucial pathological role through the presentation of self-antigens, T-cell
activation, and the production of autoantibodies and cytokines [17]. Abnormal
B-cell function is characterized by the production of a wide range of autoanti-
bodies, the serologic hallmark of SLE. Another characteristic of pathological
B-cell function is cytokine secretion: B cells produce interleukin-4, 6, 10,
interferon gamma, transforming growth factor beta, and lymphotoxin-alpha, but
in SLE, overproduction of cytokines can lead to amplification of autoimmune
response. Monoclonal gammopathy of undetermined significance (MGUS) is
defined as the presence of a monoclonal immunoglobulin (M-protein or
M-component) in the serum or urine of an individual with no evidence of multiple
myeloma, amyloid light-chain amyloidosis, Waldenström macroglobulinemia, or
other related disorders. A terminally differentiated clone of B cells secretes the
monoclonal component. MGUS is frequently associated with various connective
diseases, such as rheumatoid arthritis, SLE, scleroderma, and various infective
agents, such as hepatitis C virus, hepatitis B virus, human immunodeficiency virus,
and Helicobacter pylori. However, there is no clear evidence for a pathogenetic
role of the M-protein [18].
Visceral leishmaniasis (VL) is a parasitic disease transmitted to humans by
sandflies in endemic areas and considered endemic also in Mediterranean basin. In
Italy, the highest incidence is in the southern regions, such as Sardinia. VL
typically presents with fever, severe anorexia, hepatosplenomegaly, while labora-
tory tests show cytopenias, hypergammaglobulinemia, and elevation of acute
phase markers [19].
Autoimmune manifestations are common in VL secondary to strong T-cell
and B-cell responses. High levels of circulating immune complexes and self-
antigen are common in VL: this might be due to a release of high amounts of
antigens, as a result of tissue destruction, that may stimulate the autoreactivity and
autoantibody production. Polyclonal B-cell hyperactivation results in the severe
hypergammaglobulinemia that can be observed in VL.
VL often remains asymptomatic but may have a life-threatening course with
fever, anorexia, hepatosplenomegaly, and kidney involvement [20].
VL has been associated with multiple immunological abnormalities and owing
to its protean clinical manifestations may be misinterpreted as various autoimmune
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diseases [21]. Moreover, response to immunosuppressive treatments may masquer-
ade an undergoing VL. Serum antibodies such as ANA and anti-ds-DNA, low serum
C3 and C4 complements levels, and positive direct Coombs’ reaction are the
common SLE-related immunological findings that have been reported in the course
of VL [22]. Thus, these elements might lead to misdiagnosis of VL for SLE.
SLE and many other autoimmune diseases may have clinical and laboratory
features overlapping with VL that could hinder the right diagnosis: both can
present with fever, splenomegaly, pericardial effusion, and pancytopenia. More-
over, many autoantibodies formed in VL disease are commonly specific in
different autoimmune systemic and organ-specific diseases: anti-ds-DNA in SLE
or anti-smooth muscle antibody in autoimmune hepatitis [13, 23].
A correct and early diagnosis of VL in our patient was quite difficult; initial
response to immunosuppressive therapy further supported the SLE diagnosis.
Hematological manifestations appeared later in the clinical course and were at first
considered as a CYC side effect. Cytopenias are common in SLE, due to either
bone marrow failure, excessive peripheral cell destruction, or adverse reactions to
medication. Treatment involves steroids, steroid-sparing agents, and splenectomy
[24]. However, in our patient, discontinuation of the drugs did not completely
resolve the clinical picture, and the persistence of proteinuria and the appearance
of monoclonal gammopathy led us to reevaluate the case revealing VL diagnosis.
This is a finding reported in recent years in VL patients [25].
The emergence of monoclonal components in the course of autoimmune
diseases or in young people deserves special attention, in order to exclude a wide
range of diseases or to start an adequate follow-up program [18]. The second case
reported shares the previous case of the occurrence of a long-lasting monoclonal
gammopathy, in a patient affected by WD. This occurrence has not been reported
in the literature, as well as the elevation of ANA, anti-ds-DNA, and RNP antibody,
which are classically observed in SLE. We did not diagnose the patient as having
SLE, mainly due to the lack of consistent clinical manifestations of the disease.
However, this will not preclude that the patient (a young woman) may eventually
develop further features of SLE in the future. It is relevant to note that antibodies
showed a slow trend toward normalization, even if a larger timeframe of
observation is required.
WD is a chronic bacterial infection often characterized by malabsorption
syndrome with diarrhea and weight loss, fever, and lymphadenopathy [26]. Cases
of WD negative at bowel biopsies are documented [27]. The analysis of 16S rRNA
or novel PCR methods on biopsies and samples is essential to confirm the
diagnosis in WD or in other rare infectious diseases [7, 28].
A single case of WD and SLE has been described to date [29]. Interestingly,
although clear pathological elements of WD are recognizable, non-specific
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histopathological and clinical presentations are known [30]. Further observations
and studies may be useful to gain insight from the interaction between the immune
system and Tropheryma whipplei, which is pivotal as demonstrated by the
immune reconstitution syndrome that often arises after initializing WD treatment.
To our knowledge, this is the first report of the coexistence between WD and
persistent elevation of autoantibodies and the detection of a monoclonal
gammopathy.
In conclusion, the awareness of unusual presentations of infections, which
may be encountered in the daily clinical practice when taking care of SLE patients,
may be essential for timely diagnosis and proper treatment of such manifold and
potentially lethal diseases.
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